Most of the headlines in 2026 are about Eli Lilly — retatrutide, the triple-agonist with eye-popping 28.7% weight loss numbers, the seven Phase 3 trials still running, the constant drumbeat of “next-generation” press.
But there’s a parallel story most coverage is missing. Novo Nordisk — Lilly’s main competitor and the company that made Ozempic a household name — has been quietly running its own next-generation weight loss program. And on December 18, 2025, they filed an FDA application for CagriSema.
If approved, CagriSema would be the first FDA-approved combination weight loss drug. It would also represent a fundamentally different approach than Lilly’s. Here’s the breakdown.
What CagriSema actually is
CagriSema is two drugs in one weekly injection:
- Semaglutide (the active ingredient in Ozempic and Wegovy) at 2.4 mg
- Cagrilintide at 2.4 mg
Semaglutide you probably already know about. It activates the GLP-1 receptor, which makes you feel less hungry and slows how fast food leaves your stomach. It’s been on the market for years and is what kicked off the entire weight loss drug revolution. (For the side-by-side on how semaglutide compares to its main rival, see our breakdown of Ozempic vs Mounjaro.)
Cagrilintide is the new piece. It’s a long-acting version of amylin — a natural hormone your pancreas releases alongside insulin after meals. Amylin’s job is to tell your brain “you’re full now.” Most weight loss drugs target appetite via different pathways; cagrilintide adds a separate one. Combine them, and you’re hitting two complementary “stop eating” signals at once.
What the REDEFINE trials showed
Novo Nordisk ran two big Phase 3 trials called REDEFINE 1 (people without diabetes) and REDEFINE 2 (people with type 2 diabetes), plus REIMAGINE 2 in diabetes. Results published in The New England Journal of Medicine in mid-2025.
REDEFINE 1 (obesity, no diabetes)
- 22.7% average weight loss at 68 weeks (vs 3.0% on placebo)
- 60% of patients lost at least 20% of body weight
- 23% lost at least 30%
REDEFINE 2 (obesity with type 2 diabetes)
- 13.7% average weight loss vs 3.4% on placebo
- 73.5% achieved blood sugar control (HbA1c ≤ 6.5%)
REIMAGINE 2 (head-to-head against semaglutide)
- 14.2% weight loss vs 10.2% with semaglutide alone
- Better blood sugar control than semaglutide alone
These are strong numbers. But — and this is where Wall Street got nervous — they didn’t hit the 25% target Novo Nordisk had hinted at. The stock dropped 7% on the news.
CagriSema vs tirzepatide vs retatrutide
Here’s the head-to-head, simplified:
- Semaglutide (Wegovy) — 1 receptor (GLP-1) — ~14.9% weight loss
- Tirzepatide (Zepbound) — 2 receptors (GLP-1 + GIP) — ~22.5%
- CagriSema — 1 receptor + amylin — ~22.7%
- Retatrutide — 3 receptors (GLP-1 + GIP + glucagon) — ~28.7%
CagriSema’s efficacy lands roughly where tirzepatide is — meaningful improvement over straight Ozempic, but not a leap ahead of what Lilly already has on the market. And retatrutide, when it gets approved, is likely to set a higher ceiling.
That’s why analysts have been mixed. CagriSema is good — but it may be entering a market where it’s already the second-best option.
CagriSema side effects
GI symptoms (nausea, vomiting, diarrhea) showed up in 79.6% of CagriSema patients vs 39.9% on placebo. Most were mild-to-moderate and faded over time — typical for the GLP-1 class.
Discontinuation rate due to side effects was about 6%, vs 3.7% on placebo. That’s actually better than retatrutide’s 18% at the high dose — meaning while CagriSema doesn’t deliver as much weight loss, it’s notably easier to tolerate.
CagriSema FDA approval timeline
The FDA accepted Novo Nordisk’s NDA in late December 2025. Standard review timeline is about 10 months, so an approval decision is expected in late 2026 or early 2027.
If approved, CagriSema would be available through standard retail pharmacies — not compounding pharmacies. Insurance coverage will follow the typical GLP-1 pattern: probably covered for diabetes, harder to get covered for obesity alone.
What this means for the bigger picture
- The weight loss drug market just became a real competition. Lilly’s been winning the headlines, but Novo Nordisk has 100+ years of metabolic disease experience and a deep pipeline. They’re not done.
- Combination therapy is the next frontier. Until now, every approved weight loss drug has been a single molecule (or in tirzepatide’s case, a single molecule with two receptor effects). CagriSema is the first true combination. Expect more combinations going forward.
- The 30% weight loss ceiling is approaching. Five years ago, Wegovy’s ~15% was state-of-the-art. Now we’re looking at multiple drugs in the 22–29% range, with combination therapies probably pushing higher. The next bar — matching what bariatric surgery achieves long-term — is well within reach.
For research labs, the implication is that the field is no longer just about GLP-1. Amylin agonists, glucagon agonists, and combination strategies are all opening up. The pipeline is wider than it was 18 months ago.
Strictly for qualified research use only. Nothing in this article should be construed as medical advice.
